Cytek Biosciences (CTKB) Liabilities and Shareholders Equity (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $449.1 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 6.94% year-over-year to $449.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 billion (down 2.97% YoY), and the FY2025 full-year result was $461.5 million, down 7.6% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $449.1 million, down from $461.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $525.1 million in Q2 2023 and bottomed at $449.1 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $493.3 million (2025), against an average of $494.6 million.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity jumped 114.01%; it then decreased 7.87% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $519.5 million in 2022, then decreased by 4.82% to $494.5 million in 2023, then gained by 1.02% to $499.5 million in 2024, then fell by 7.6% to $461.5 million in 2025, then slipped by 2.69% to $449.1 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $449.1 million (Q1 2026), $461.5 million (Q4 2025), and $494.9 million (Q3 2025), per Business Quant data.

Peer Comparison